USFDA Issues 8 Observations for Sun Pharma Halol Plant Operations

Sun Pharma, India's largest drug manufacturer, announced on June 14, 2025, that the US Food and Drug Administration (USFDA) conducted an inspection at its Halol manufacturing facility in Gujarat from June 2-13, 2025. Following the inspection, the USFDA issued a Form 483 with 8 observations, highlighting areas of concern related to good manufacturing practices (GMP).

According to the USFDA, a Form 483 is issued to a company when an inspection identifies potential violations of the Food, Drug, and Cosmetic Act or related regulations. While the specific details of the 8 observations remain undisclosed, Sun Pharma has stated it is committed to addressing the issues raised and ensuring compliance with global regulatory standards.

This is not the first time the Halol facility has been under scrutiny. Observations in past inspections have led to significant operational and regulatory challenges for the company. The latest findings could potentially impact product approvals from this site, which plays a critical role in Sun Pharma's global supply chain.

The company plans to respond to the USFDA promptly and implement corrective measures to resolve all noted concerns. These developments underscore the importance of strict regulatory compliance in maintaining market credibility.